Scaffold Therapeutics is developing molecules for treatment of solid tumors and rare neurodegenerative disorders like ALS. Our lead asset is strongly differentiated by its ability to readily penetrate the brain after a single dose while competitor compounds are not available in the brain. We are initially targeting liver cancer and glioblastoma.